Arabic Arabic English English French French German German
dark

SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate

GlaxoSmithKlineSK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase 1/2 results.

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Benefitfocus taps new marketing head

Next Post

Insurer dispute complicates Boy Scouts abuse claims payout

Related Posts
Total
0
Share